163 related articles for article (PubMed ID: 7479193)
1. Revised FDA labeling guideline for theophylline oral dosage forms.
Hendeles L; Jenkins J; Temple R
Pharmacotherapy; 1995; 15(4):409-27. PubMed ID: 7479193
[No Abstract] [Full Text] [Related]
2. Plasma theophylline levels in asthmatic children in Singapore. A preliminary study.
Lee HS; Ngiam TE
Singapore Med J; 1983 Oct; 24(5):276-9. PubMed ID: 6669990
[No Abstract] [Full Text] [Related]
3. FDA notifications. New labeling for Videx pediatric powder.
AIDS Alert; 2009 Aug; 24(8):94-6. PubMed ID: 19705588
[No Abstract] [Full Text] [Related]
4. FDA notifications. Lopinavir/ritonavir label updated.
AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18727173
[No Abstract] [Full Text] [Related]
5. Retrovir efficacy supplement approved.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043841
[No Abstract] [Full Text] [Related]
6. A steady state comparison of three theophylline formulations in adult stable asthmatics.
Subramaniam S; Dhand R; Garg SK; Sharma PL
Indian J Med Res; 1988 May; 87():509-15. PubMed ID: 3169909
[No Abstract] [Full Text] [Related]
7. New pediatric dosage rules: information and testing.
Feeg VD
Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
[No Abstract] [Full Text] [Related]
8. Proposed NSAID package insert labeling.
Food and Drug Administration U.S. Public Health Service
J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
[TBL] [Abstract][Full Text] [Related]
9. FDA perspectives on supplement use by patients on antithrombotic therapy.
Kim MJ
Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
[No Abstract] [Full Text] [Related]
10. FDA notifications. Agenerase product label changed.
AIDS Alert; 2002 Oct; 17(10):131. PubMed ID: 12400469
[No Abstract] [Full Text] [Related]
11. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
Woo JJ
Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
[No Abstract] [Full Text] [Related]
12. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
[No Abstract] [Full Text] [Related]
13. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
[No Abstract] [Full Text] [Related]
14. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
15. FDA puts forth proposal to mandate patient information.
Wechsler J
Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
[No Abstract] [Full Text] [Related]
16. FDA notifications. FDA approves label change for nevirapine.
AIDS Alert; 2008 Aug; 23(8):91-2. PubMed ID: 18724490
[No Abstract] [Full Text] [Related]
17. Is pediatric labeling really necessary?
Christensen ML; Helms RA; Chesney RW
Pediatrics; 1999 Sep; 104(3 Pt 2):593-7. PubMed ID: 10469796
[No Abstract] [Full Text] [Related]
18. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
19. Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Apr; 68(74):18861-9. PubMed ID: 12701599
[TBL] [Abstract][Full Text] [Related]
20. Massive theophylline overdose. Survival without hemoperfusion.
Dean LS; Brown JW
JAMA; 1982 Oct; 248(14):1742. PubMed ID: 6811769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
